Next Article in Journal
USP22 Promotes NSCLC Tumorigenesis via MDMX Up-Regulation and Subsequent p53 Inhibition
Next Article in Special Issue
Potential Relationship between Inadequate Response to DNA Damage and Development of Myelodysplastic Syndrome
Previous Article in Journal
Molecular Targets of Antihypertensive Peptides: Understanding the Mechanisms of Action Based on the Pathophysiology of Hypertension
Previous Article in Special Issue
Oxidative Stress and Its Significant Roles in Neurodegenerative Diseases and Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 16
Issue 1
10.3390/ijms16010284
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

The Anticancer Drug Ellipticine Activated with Cytochrome P450 Mediates DNA Damage Determining Its Pharmacological Efficiencies: Studies with Rats, Hepatic Cytochrome P450 Reductase Null (HRN™) Mice and Pure Enzymes

by
Marie Stiborová
1,*,
Věra Černá
1,
Michaela Moserová
1,
Iveta Mrízová
1,
Volker M. Arlt
2 and
Eva Frei
3
1
Department of Biochemistry, Faculty of Science, Charles University, Hlavova 2030, CZ-12843 Prague 2, Czech Republic
2
Analytical and Environmental Sciences Division, MRC-PHE Centre for Environmental & Health, King’s College London, 150 Stamford Street, London SE1 9NH, UK
3
Division of Preventive Oncology, National Center for Tumor Diseases, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2015, 16(1), 284-306; https://doi.org/10.3390/ijms16010284
Submission received: 19 October 2014 / Accepted: 17 December 2014 / Published: 25 December 2014
(This article belongs to the Special Issue DNA Damage and Repair in Degenerative Diseases 2014)
Browse Figures
Versions Notes

Abstract

Ellipticine is a DNA-damaging agent acting as a prodrug whose pharmacological efficiencies and genotoxic side effects are dictated by activation with cytochrome P450 (CYP). Over the last decade we have gained extensive experience in using pure enzymes and various animal models that helped to identify CYPs metabolizing ellipticine. In this review we focus on comparison between the in vitro and in vivo studies and show a necessity of both approaches to obtain valid information on CYP enzymes contributing to ellipticine metabolism. Discrepancies were found between the CYP enzymes activating ellipticine to 13-hydroxy- and 12-hydroxyellipticine generating covalent DNA adducts and those detoxifying this drug to 9-hydroxy- and 7-hydroellipticine in vitro and in vivo. In vivo, formation of ellipticine-DNA adducts is dependent not only on expression levels of CYP3A, catalyzing ellipticine activation in vitro, but also on those of CYP1A that oxidize ellipticine in vitro mainly to the detoxification products. The finding showing that cytochrome b5 alters the ratio of ellipticine metabolites generated by CYP1A1/2 and 3A4 explained this paradox. Whereas the detoxification of ellipticine by CYP1A and 3A is either decreased or not changed by cytochrome b5, activation leading to ellipticine-DNA adducts increased considerably. We show that (I) the pharmacological effects of ellipticine mediated by covalent ellipticine-derived DNA adducts are dictated by expression levels of CYP1A, 3A and cytochrome b5, and its own potency to induce these enzymes in tumor tissues, (II) animal models, where levels of CYPs are either knocked out or induced are appropriate to identify CYPs metabolizing ellipticine in vivo, and (III) extrapolation from in vitro data to the situation in vivo is not always possible, confirming the need for these animal models.
Keywords: anticancer drug ellipticine; cytochrome P450 mediated DNA-damage; covalent DNA adducts; enzymes metabolizing ellipticine in vitro and in vivo anticancer drug ellipticine; cytochrome P450 mediated DNA-damage; covalent DNA adducts; enzymes metabolizing ellipticine in vitro and in vivo

Share and Cite

MDPI and ACS Style

Stiborová, M.; Černá, V.; Moserová, M.; Mrízová, I.; Arlt, V.M.; Frei, E. The Anticancer Drug Ellipticine Activated with Cytochrome P450 Mediates DNA Damage Determining Its Pharmacological Efficiencies: Studies with Rats, Hepatic Cytochrome P450 Reductase Null (HRN™) Mice and Pure Enzymes. Int. J. Mol. Sci. 2015, 16, 284-306. https://doi.org/10.3390/ijms16010284

AMA Style

Stiborová M, Černá V, Moserová M, Mrízová I, Arlt VM, Frei E. The Anticancer Drug Ellipticine Activated with Cytochrome P450 Mediates DNA Damage Determining Its Pharmacological Efficiencies: Studies with Rats, Hepatic Cytochrome P450 Reductase Null (HRN™) Mice and Pure Enzymes. International Journal of Molecular Sciences. 2015; 16(1):284-306. https://doi.org/10.3390/ijms16010284

Chicago/Turabian Style

Stiborová, Marie, Věra Černá, Michaela Moserová, Iveta Mrízová, Volker M. Arlt, and Eva Frei. 2015. "The Anticancer Drug Ellipticine Activated with Cytochrome P450 Mediates DNA Damage Determining Its Pharmacological Efficiencies: Studies with Rats, Hepatic Cytochrome P450 Reductase Null (HRN™) Mice and Pure Enzymes" International Journal of Molecular Sciences 16, no. 1: 284-306. https://doi.org/10.3390/ijms16010284

APA Style

Stiborová, M., Černá, V., Moserová, M., Mrízová, I., Arlt, V. M., & Frei, E. (2015). The Anticancer Drug Ellipticine Activated with Cytochrome P450 Mediates DNA Damage Determining Its Pharmacological Efficiencies: Studies with Rats, Hepatic Cytochrome P450 Reductase Null (HRN™) Mice and Pure Enzymes. International Journal of Molecular Sciences, 16(1), 284-306. https://doi.org/10.3390/ijms16010284

Article Metrics

Back to TopTop